Reglagene, a Tucson-based developer of quadruplex master switch technology that enables the discovery of medicines that control gene expression, placed second in the RESI Innovation Challenge during JPM Week in San Francisco. Hosted by Life Science Nation (LSN), RESI conferences bring together global early-stage companies across Biotech, Medtech, Diagnostics & Digital Health with life science strategics, family offices, venture funds and angel investors. Continue reading
Author Archive: AZBio
Medtronic Wins Prestigious CATALYST Award
Jan. 16, 2020: Women play a vital role at Medtronic. From engineers building pacemakers and insulin pumps to sales representatives working in communities around the world, women at all levels of the organization are driving the company’s efforts to transform healthcare.
Funding Opportunity Alert – Healthy Longevity Global Competition
The Healthy Longevity Global Competition, founded by the U.S. National Academy of Medicine and supported by J&J Innovation is a global movement to extend the human healthspan by accelerating research, innovation, and entrepreneurism in healthy longevity. Awards of $50,000 are available. Apply before February 24, 2020.Continue reading
NAU engineer developing innovative biomaterial for improved treatment of cerebral aneurysms
Tim Becker, an associate professor of practice in the Department of Mechanical Engineering at Northern Arizona University, is developing a polypropylene glycol-based biomaterial called PPODA-QT, which is similar to body tissue, to treat aneurysms in the brain and improve outcomes for stroke and potential stroke patients.Continue reading
OncoMyx Therapeutics Announces Formation of Scientific Advisory Board
PHOENIX, January 9, 2020 – OncoMyx Therapeutics, a privately-held oncolytic immunotherapy company, announced today the formation of its Scientific Advisory Board (SAB), comprised of experts in tumor immunology, oncology drug discovery and development, and oncolytic viruses. The SAB will work closely with the OncoMyx leadership team as the company advances a therapeutic pipeline of oncolytic immunotherapies based on the myxoma virus (MYXV) platform. The company’s pipeline includes both monotherapies and therapies to be used in combination with immune checkpoint blockade and other immuno-modulatory approaches, offering significant therapeutic promise to a wide range of cancer targets.Continue reading
January is National Biotechnology Month
On January 1, 2020, President Trump proclaimed January 2020 as National Biotechnology Month. Continue reading
FDA Approved 52 New Drugs in 2019
With 52 Novel Drug Approvals and 4 Biologic License Application (BLA) approvals, 2019 takes its place as the second most prolific year for approvals in the last two decades. The record high goes to 2018 with 59 approvals and the record low to 2002 with 17. (Source)
Read on to see the AZBio Member Companies that received approvals…
Genes in Space – A Special Opportunity for Students in Grades 7 – 12
Announcing Genes in Space 2020 – Design and Launch Your DNA Experiment to Space!
Calling all students in grades 7 through 12: Have you ever wondered how astronauts might survive a deep-space mission or how we might be able to use biology to transform new worlds? If so, Genes in Space is for you!Continue reading
BIO5’s Victor Hruby Elected as a Fellow of the National Academy of Inventors
Election to NAI Fellow status is a high professional distinction granted to academic inventors who have demonstrated a prolific spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development and the welfare of society.Continue reading